After stratifying the patients with residual disease into the Ki67% groups (no changes and decreased levels; patients with increased levels were removed due to the small sample size), the incidence of death from breast cancer and other causes was highest for patients with no changes in Ki67% (Fig. 4B). This evidence concerns the gene MKI67 and breast carcinoma.